Good-first: B/F/TAF As First-line ART

This study is evaluating a specific HIV treatment — B/F/TAF (bictegravir/emtricitabine/tenofovir alafenamide, brand name Biktarvy) — as a first-line antiretroviral therapy (ART) for people newly diagnosed with HIV. Researchers are comparing it to older regimens (TDF+3TC+EFV or DTG/3TC) to see how well it works and how safe it is in a real-world setting. **You may be eligible if...** - You are 18 or older and have been diagnosed with HIV/AIDS - You have never taken HIV medications before (ART-naive) - You were diagnosed between July 2024 and June 2025 (prospective enrollment) or January 2020 and June 2023 (retrospective review) - You are eligible to start B/F/TAF or were previously treated with TDF+3TC+EFV or DTG/3TC - You are willing to follow study visits or have complete electronic health records available **You may NOT be eligible if...** - You have severe kidney problems (creatinine clearance under 50 mL/min) - You have hepatitis B co-infection or severe liver disease - You have active tuberculosis (TB) Talk to your doctor to see if this trial is right for you.